2011-09-14Zeitschriftenartikel DOI: 10.1093/infdis/jir613
Influenza B Virus With Modified Hemagglutinin Cleavage Site as a Novel Attenuated Live Vaccine
Mettenleiter, Thomas C.
Background: Both pandemic and interpandemic influenza is associated with high morbidity and mortality worldwide. Seasonal epidemics are caused by both influenza A and B virus strains that cocirculate with varying predominance and may give rise to severe illness equally. According to World Health Organization recommendations, current annual vaccines are composed of 2 type A and 1 type B virus-specific component. Methods: As a novel attenuated live vaccine against influenza B virus, we generated a hemagglutinin cleavage site mutant of strain B/Lee/40 by replacing the common monobasic cleavage site recognized by trypsinlike proteases with an elastase-sensitive site, and we investigated the in vitro properties, attenuation, humoral responses, and efficacy in mice. Results. This mutant virus replicated in cell culture equally well as the wild type but in a strictly elastase-dependent manner. In contrast to the mouse-pathogenic parental virus, the cleavage site mutant was fully attenuated in mice and not detectable in their lungs. After 1 intranasal immunization, the animals survived lethal challenge with wild-type virus without weight loss or any other signs of disease. Furthermore, no challenge virus could be reisolated from the lungs of vaccinated mice. Conclusions: These findings demonstrate that proteolytic activation mutants can serve as live vaccine against influenza B virus.
Dateien zu dieser Publikation
Anzeige der Publikationen mit ähnlichem Titel, Autor, Urheber und Thema.
2016-10-13ZeitschriftenartikelImproving influenza virological surveillance in Europe: strain-based reporting of antigenic and genetic characterisation data, 11 European countries, influenza season 2013/14 Broberg, E.; Hungnes, Olav; Schweiger, Brunhilde; Prosenc, Katarina; Daniels, R.; Guiomar, R.; Ikonen, N.; Kossyvakis, A.; Pozo, Francisco; Puzelli, S.; Thomas, I.; Waters, A.; Wiman, Å.; Meijer, AdamInfluenza antigenic and genetic characterisation data are crucial for influenza vaccine composition decision making. Previously, aggregate data were reported to the European Centre for Disease Prevention and Control by ...
2011-03-16ZeitschriftenartikelJoint production of prime/boost pairs of Fowlpox Virus and Modified Vaccinia Ankara recombinants carrying the same transgene Soprana, Elisa; Panigada, Maddalena; Knauf, Mathias; Radaelli, Antonia; Vigevani, Luisa; Palini, Alessio; Villa, Chiara; Malnati, Mauro; Cassina, Giulia; Kurth, Reinhard; Norley, Stephen; Siccardi, Antonio G.Pairs of recombinant MVA (Modified Vaccinia Ankara) and FPV (Fowlpox Virus) expressing the same transgene are reasonable candidates for prime/boost regimens, because cross-reacting immune responses between the two vectors, ...
2015-04-28ZeitschriftenartikelThe European I-MOVE Multicentre 2013–2014 Case-Control Study. Homogeneous moderate influenza vaccine effectiveness against A(H1N1)pdm09 and heterogenous results by country against A(H3N2) Valenciano, Marta; Kissling, Esther; Reuss, Annicka; Jiménez-Jorge, Silvia; Horváth, Judit K.; Donnell, Joan M.O.; Pitigoi, Daniela; Machado, Ausenda; Pozo, FranciscoBackground: In the first five I-MOVE (Influenza Monitoring Vaccine Effectiveness in Europe) influenza seasons vaccine effectiveness (VE) results were relatively homogenous among participating study sites. In 2013–2014, ...